The GLP-1 boom is the biggest pharma story of the decade. Ozempic and Wegovy can now be ordered from a telehealth app on a monthly subscription.
After Novo Nordisk threatened to sue over compounded knockoffs, today's standout pivoted and cut deals with both Novo and Eli Lilly, becoming the consumer face of the era.
Novo went from threatening to sue Hims for ripping off Wegovy to being its distribution partner inside a few weeks.
After some corrective action, one of the cycle’s best stocks is setting up once more.
Hims & Hers Health Inc $HIMS is currently exhibiting a Squeeze Score of 94.3.
Here’s what the chart looks like:
HIMS is coiled tightly as price carves out a reversal pattern following an 80% drawdown from its all-time highs.
The stock has already completed one successful countertrend move and is now attempting to break out from a second bullish flag. With each consolidation occurring at a higher level, buyers continue to gain ground.
Volatility on the Strazza Indicator has reset following the recent expansion phase, creating the conditions for another directional move.
